Mechanism of Action

TPL101 inhibits a nuclear import protein (as illustrated below) critical in the replication cycle of a range of viruses. This means that our TPL101 should be consistently effective against a range of coronaviruses including COVID-19 and Avian influenza as well as Flaviviridae infections including Dengue, Zika, and Yellow Fever. Moreover, this mechanism of action also implies that TPL101 should be strain agnostic in its antiviral effect. In addition, the components of TPL101 also have minor direct and indirect inhibitory effects on COVID-19 cell binding via cell receptors which may also carry over to other viruses.  

TPL101 has also been demonstrated in our studies to exhibit a powerful anti-inflammatory effect by significantly reducing the expression of IL-1β, IL-6, TNF-α, IP-10, IFN-λ1, IL-8, IL-12p70, IFN-α2, IFN-λ2/3, GM-CSF, IFN-β, IL-10 and IFN-γ.